
PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring ...
If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) Data to be part of a planned US FDA filing in H2 2025 An estimated 2.9 million cases of cUTIs are treated annually …